Información del producto
- Ar-H 053591
- Biie-0246
- Cyclopentaneacetamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-
- N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]cyclopentaneacetamide
- N5-(diaminomethylidene)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N2-[(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-L-ornithinamide
BIIE 0246 is a neuroactive peptide that is involved in the regulation of neuronal death. It has been shown to be a metabolic regulator, with effects on the epididymal adipose tissue, and also an immunomodulator. BIIE 0246 has been shown to induce autoimmune diseases in vivo by inhibiting the production of inflammatory cytokines. It has been used as an inhibitor of enzymes such as phospholipase A2, which are involved in inflammation and lipid metabolism. BIIE 0246 also inhibits the angiotensin II type 1 receptor (AT1), which regulates blood pressure and cardiac function. This drug also has locomotor activity-inducing effects, resulting in increased motor activity and reduced immobility time on a rotarod test, as well as memory-enhancing properties that have been observed through changes in hippocampal formation activity.
Propiedades químicas
Consulta técnica sobre: 3D-WJA14655 BIIE 0246
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.